indazoles has been researched along with Macular Edema in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kompella, UB; Rao, VR; Scheinman, RI; Thakur, A | 1 |
| Eibl, K; Haritoglou, C; Kampik, A; Kernt, B; Kernt, M; Liegl, RG; Thiele, S; Ulbig, MW | 1 |
2 other study(ies) available for indazoles and Macular Edema
| Article | Year |
|---|---|
Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage.
Topics: Administration, Ophthalmic; Animals; Blood Glucose; Blood Proteins; Blood-Retinal Barrier; Body Weight; Capillary Permeability; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Indazoles; Leukocytes; Leukostasis; Macular Edema; Male; Molecular Targeted Therapy; Ophthalmic Solutions; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Rats; Rats, Inbred BN; Sulfonamides; Time Factors; Vitreous Body | 2011 |
Axitinib modulates hypoxia-induced blood-retina barrier permeability and expression of growth factors.
Topics: Adult; Aged; Axitinib; Blood-Retinal Barrier; Cell Hypoxia; Cell Membrane Permeability; Cell Survival; Cells, Cultured; Diabetic Retinopathy; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Indazoles; Intercellular Signaling Peptides and Proteins; Macular Edema; Middle Aged; Pigment Epithelium of Eye; Receptor, Platelet-Derived Growth Factor beta; RNA, Messenger; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2012 |